Lupin set for worldwide launch of 50 products in next fiscal year

Indian pharma major Lupin is all set to launch nearly 50 products in the global markets in the current fiscal. The company has filed 21 abbreviated new drug applications (ANDAs) in the US market in the last fiscal, and is planning to launch 10-12 products in the current fiscal which are likely to get cleared for launch within the fiscal.

The Managing Director of the company issued a statement saying that it is close to about 100 filings [for the US] that are still awaiting approvals. Lupin will continue to make about 25-30 filings specifically in niche areas and has always focused on control released, sustained release products which are difficult to develop, enjoy higher margins and have less competition as one requires scale as well as technology and IP prowess to develop them."

The firm is planning a worldwide launch of 50 products of which 30 products will be launched in India. Through its Japanese subsidiary Kyowa Pharmaceutical, the company is also planning to launch 10 products in Japan in the current fiscal.